The innovative approach involves the genetic modification of a patient’s own T cells to express a receptor targeting specific tumor antigens, enabling effective cytolysis of tumor cells in a major histocompatibility complex (MHC)-independent manner. The gene discussed is HLA-C; the disease is neoplasm.